A collaborative approach to home OKT3 infusion therapy.

Hospitalization of patients who have undergone renal transplantation is often extended because of the need to complete complex antirejection infusion therapy. Because of the costs associated with prolonged hospitalization, medical professionals who provide care to these patients are developing programs that will facilitate attainment of quality care in the outpatient setting. The authors describe the effective implementation of a home Muromonab-CD3 (OKT3) intravenous administration program among renal transplant recipients based on thorough planning and close collaboration between the transplant service and home care staff.